Ahead of the event, recently released CPHI findings show 65% of US companies are predicting growth in excess of 20% in 2022 – with CDMOs reporting the highest rates
Informa Markets has announced CPHI North America will be held as a SMART event, with a digital component live from the 9-27 May and an in-person event held from the 17-19.
The SMART event format stimulates greater industry collaboration, Informa says. Buyers and sellers are able to actively research partners ahead of attendance, before hosting meetings digitally or in-person at the event – which will be held at the Pennsylvania Convention Center.
Adam Andersen, Executive VP, Pharma at Informa Markets, said: “Everything we do at CPHI is to facilitate industry partnering and it’s in these vital face to face interactions that conversations take on greater depth and deals are signed that will deliver pharma’s future growth.”
The event’s conference programme will span four tracks: US market insights, biologics and bioprocessing, drug manufacturing dynamics, and navigating supply chain and capacity challenges. Sessions will explore the impacts of continuous manufacturing adoption, reshoring, ESG initiatives, COVID therapeutics, and the implications for innovators of the novel excipients pilot programme.
The event also features a dedicated bioprocessing track launched in collaboration with the Jefferson Institute of Bioprocessing and an NSF International training course (additional fee applies) on ‘corrective and preventive actions (CAPAs) based on the identified root cause’.
Ahead of the event, recently released CPHI findings show 65% of US companies are predicting growth in excess of 20% in 2022 – with CDMOs reporting the highest rates.
Nearly half (45%) of US based companies said they expected ‘a capacity crunch at CDMOs in the next year due to surging approvals’.
In fact, two thirds of respondents believe this surging growth will cause the emergence of a two-tier market, in which large and medium pharma align with strategic partners, while smaller biotechs may potentially struggle to find appropriate outsourcing partners.
Andersen said: “Pharma companies in North America are predicting high levels of growth in 2022, particularly manufacturers and CDMOs. This is driven by new drug products entering the market, the success of recent approvals, and macro changes in the location of manufacturing. Underpinning this is a widening and diversifying pharma supply chain – which is why CPHI North America has such an important role to play in enabling the industry to source, connect and learn.”
Registration is free to all until April 10th and, highlighting the importance of the event to buying and partnering, 48% of CPHI North America attendees are C-suite level, with 65% having purchasing responsibility.
CPHI North America spans the entire pharma supply chain from ingredients, finished dose, contract services and fine chemicals to biologics, packaging, and machinery, with seven collocated events, for more information please visit: www.CPHI.com/northamerica/en